Xanthelasma palpebrarum is a benign periorbital xanthoma with substantial cosmetic and psychosocial burden for patients. Treatment modalities should be considered based on efficacy as well as cosmetic outcome. Laser modalities in the treatment of xanthelasma palpebrarum have not been comprehensively reviewed and discussed. Accordingly, this study seeks to systematically and critically review the available literature discussing laser treatment of xanthelasma palpebrarum. PubMed was systematically reviewed for reports on laser therapy in the treatment of xanthelasma palpebrarum. A total of 21 studies were included in this review discussing laser treatment of xanthelasma palpebrarum. Laser types included carbon dioxide, yttrium aluminum garnet, pulsed dye, argon, and a 1450 nm diode laser. The carbon dioxide laser was the most commonly reported modality followed by yttrium aluminum garnet laser. All of the laser modalities offered moderate to excellent clearance rates with minimal side effect profiles. Further large scale studies comparing different laser modalities are required to determine the best laser modality. However, laser modalities as a whole offer a treatment option for xanthelasma palpebrarum, that is, cosmetically excellent with a reasonable side-effect profile.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ijd.13534 | DOI Listing |
J Clin Aesthet Dermatol
November 2024
All authors are affiliated with the Institute of Cosmetic and Laser Surgery in Oakville, Ontario. Canada.
Objective: We sought to analyze the effectiveness, recurrence, safety, and patient satisfaction rates following xanthelasma palpebrarum (XP) treatment with trichloroacetic acid (TCA) 80%.
Methods: This was a retrospective review of patients treated with TCA 80% for XP between January 2012 and August 2022. A prospective telephone questionnaire was administered to the same patient population to evaluate recurrence, patient satisfaction, and side effects.
Lasers Med Sci
January 2025
Department of Plastic and Reconstructive Surgery, Korea University College of Medicine, Korea University Anam Hospital, Seoul, South Korea.
Xanthelasma palpebrarum (XP), characterized by soft, yellowish plaque primarily on the eyelids, is often associated with lipid metabolism disorders. XP can cause aesthetic concerns that affect social interactions and requires careful treatment evaluations due to potential complications and associations with systemic conditions. We aimed to assess the efficacy of and recurrence rates with erbium:yttrium aluminum garnet (Er:YAG) laser therapy in the treatment of XP.
View Article and Find Full Text PDFDermatol Pract Concept
October 2024
Department of Dermatology, Venereology and Leprosy, Teerthanker Mahaveer Medical College and Research Centre, Moradabad, Uttar Pradesh, India.
Introduction: Xanthelasma palpebrarum is considered to be a cutaneous marker for cardiovascular diseases, and there is a known association with hypertension, insulin resistance, diabetes mellitus, obesity, and stroke.
Objectives: Our aim was to study the association and identify the predictors of metabolic syndrome in patients with xanthelasma palpebrarum.
Methods: An observational study was conducted on 55 patients in which patients of both sexes ages 20-70 years without any other skin condition were included after written informed consent.
Aesthetic Plast Surg
December 2024
Department of Plastic and Reconstructive Surgery, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui Province, People's Republic of China.
Background: Xanthelasma palpebrarum (XP) is a common eyelid condition. Various treatment modalities exist, each with its own merits and drawbacks. Managing larger lesions poses increased challenges.
View Article and Find Full Text PDFArch Dermatol Res
September 2024
Department of Plastic and Reconstructive Surgery, East Hospital, Affiliated to Tongji University, No. 150, Jimo Road, Pudong New District, Shanghai, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!